Thomas R. Beck, M.d.
Chief Medical Officer
United States of America
Tom Beck M.D., is the Chief Medical Officer of Promentis and is an Executive Partner at F-Prime Capital. Tom joined F-Prime as an Executive Partner in September 2007. Most recently he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc. (Chairman and Chief Executive Officer), and Enzytech, Inc. (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., Symbiomix Therapeutics, and Akriveia Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics, and currently is Head, Research and Development at Symbiomix.
Internal Medicine, Nephrology, Clinical development and Business development.